Sandoz Fights Amgen's Bid To Halt 1st Biosimilar Launch

Law360, New York (April 27, 2015, 5:43 PM ET) -- Sandoz Inc. urged the Federal Circuit to deny Amgen Inc.'s emergency bid to bar Sandoz's launch of the first-ever biosimilar drug under the Affordable Care Act, saying Friday the district court that denied the same request did not abuse its discretion or err in its factual findings.



Princeton, New Jersey-based Sandoz told the appeals court that Amgen is making a novel argument that it is entitled to such an order under state law. Sandoz said the request should be denied.



Amgen has failed to show that...

To view the full article, register now.